Ironwood Pharmaceuticals, Inc. announces Board changes. Published on 10/16/2026 at 10:36 am EDT S&P Capital IQ Ironwood Pharmaceuticals, Inc. increased the size of the Board from eight to nine directors and elected Tammi Gaskins as a director, in each case, effective as of January 1, 2027. Mr. McCourt will continue to serve as a director on the Board following his retirement as Chief Executive Officer. Tammi has been a leader in Ironwood's commercial organization since joining the company in 2020 playing a critical role establishing LINZESS as the number one prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). She has also led commercial development efforts for apraglutide, a potential best-in-class, once-weekly GLP-2 analog in Phase 3 development for the treatment of adults with short bowel syndrome with intestinal failure (SBS-IF). Prior to joining Ironwood, Tammi held commercial leadership roles of increasing responsibilities during a 20-year tenure at AstraZeneca. Tom joined Ironwood as its first Chief Commercial Officer helping to shape the clinical profile of LINZESS to enable its commercial success. Building the commercial organization from the ground up, Tom and the team collaborated closely with multiple LINZESS partners over the years to grow it into a blockbuster brand. After becoming CEO in 2021, he led the effort to acquire VectivBio bringing apraglutide to Ironwood's late-stage pipeline. Before Ironwood, Tom made significant contributions to the commercial and drug development efforts for several market-leading brands at Merck, Astra Merck, AstraZeneca, Novartis and Amgen. (C) S&P Capital IQ - 2026

Ironwood Pharmaceuticals reported stronger second-quarter results, with LINZESS US sales rising 14% to $282.3 million. The company raised its 2026 LINZESS guidance to $1.15 billion-$1.2 billion. Ironwood began enrolling patients in the confirmatory Phase III STARS-2 trial for apraglutide, a treatment for short bowel syndrome with intestinal failure. The company is working to accelerate recruitment. The pharmaceutical firm repaid $200 million in convertible notes and raised its 2026 revenue guidance to $460 million-$485 million. Adjusted EBITDA is expected to exceed $310 million. Chief executive Thomas McCourt said the company remains focused on maximising LINZESS performance, advancing apraglutide, and delivering sustained profitability and cash flow.

Ironwood Pharmaceuticals has raised its full-year 2026 financial guidance following strong second-quarter results. The company now expects LINZESS U.S. net sales of $1.15–$1.20 billion, representing over 30% year-over-year growth, with total revenue guidance raised to $460–$485 million and adjusted EBITDA to greater than $310 million. In Q2 2026, LINZESS U.S. net sales reached $282 million, whilst year-to-date sales hit $555 million, marking 44% year-over-year growth. The company reported total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million for the quarter. Ironwood repaid $200 million in convertible notes using cash on hand and has begun actively recruiting patients for its confirmatory Phase 3 STARS-2 trial of apraglutide for short bowel syndrome with intestinal failure.